Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

A user reported noticeable hair regrowth using a 272 diode red light therapy hat over 11 months without Minoxidil or Finasteride. Opinions vary on its effectiveness compared to traditional treatments, with some suggesting combining therapies for better results.

Korean scientists developed a red light therapy that reduces a hair loss marker by 92%. Users discussed the benefits and drawbacks of natural sunlight versus red light caps for hair health, with some suggesting supplements for vitamin D.

The conversation is about whether to use gloves when applying 5% RU58841 to avoid systemic absorption and if washing hands with water is sufficient. Users question the concern, noting it is applied to the scalp.

KPV, a peptide patented by L'Oreal, may promote hair growth and reduce hair loss by extending the anagen phase and has anti-inflammatory properties. It could be combined with treatments like minoxidil for enhanced effects.

RU58841 is discussed for hair loss treatment, with questions about its legitimacy from RUdirect. Minoxidil and finasteride are also mentioned as treatments.

PP405 shows initial promise for treating androgenetic alopecia, with safety confirmed in early trials, but skepticism remains due to limited data. Further trials are needed to determine its true efficacy and potential market impact.

The conversation is about the difficulty of applying both pyril and min/fin to treat hair loss twice daily and whether combining them yields positive results.

The post and conversation are about the high cost and skepticism surrounding pyrilutamide as a hair loss treatment, with comparisons to minoxidil, finasteride, and RU58841. The original poster defends pyrilutamide's effectiveness and criticizes others for dismissing it without proper understanding.

RU58841 is used by some for hair loss when finasteride and minoxidil are ineffective. Users report mixed results, with some experiencing side effects like chest pain and mood changes.

A user tried the Rapid Minoxidil Response Test (TrichoGene) and found they don't respond to topical Minoxidil, so they added tretinoin. The test is available internationally, and another user is considering ordering it.

The conversation discusses obtaining RU58841 in Germany without international shipping, with users sharing experiences and advice. The original poster has been using RU58841 for three years and is seeking local sources to avoid customs issues.

A 19-year-old male is experiencing hair loss and is trying rosemary oil with a carrier oil and derma rolling before considering Minoxidil. Others share their experiences with finasteride, Minoxidil, and various oils, noting potential side effects and personal preferences.

There are no updates on GT20029, and concerns about its safety and effectiveness remain. The phase III trial has not started, and there are no new studies or data releases.

A user taking dutasteride and minoxidil for hair loss is considering adding RU58841 to their regimen due to unsatisfactory results. Other users suggest alternatives and discuss the potential temporary benefits and limitations of RU58841.

The conversation discusses using Pyrilutamide, Alfatradiol 0.1%, and Minoxidil for hair loss treatment. Pyrilutamide is described as a strong antiandrogen, and Alfatradiol is noted for its effectiveness in inhibiting DHT on the scalp.

Red light therapy with dual wavelengths (650nm and 850nm) can stimulate hair regrowth without DHT blockers. Consistent use of a panel with these wavelengths has shown positive results in hair regrowth.

A user discussed a significant hair recovery using alfatradiol and fluridil but was considered untrustworthy and the post was deleted. They are seeking the original poster's username.

Pyrilutamide and RU58841 are androgen receptor antagonists that block receptors without significantly reducing testosterone or DHT levels. Any indirect effect on androgen levels is likely negligible.

PRP treatments have been effective for the user, with a new recommendation of using a high-quality plasma kit once a year. The user seeks experiences with this specific PRP approach.

RU58841 is used by some for hair loss, with mixed results; one user reported success with no side effects, while another experienced lung and heart issues. RU58841 is often sourced from third-party vendors and used alongside treatments like dutasteride and minoxidil.

The conversation discusses hair regrowth progress using Minoxidil, finasteride, and RU58841. It highlights the transformation of vellus hairs into terminal hairs in a Norwood 6 frontal area.

RU58841 remains active for several hours after application, and it's suggested to wait a few hours before washing it off to maintain its effectiveness. There is a concern about potential transfer to others if they touch the hair shortly after application.

RU58841's legitimacy and sourcing concerns. Users suggest caution and recommend trusted sources over platforms like Amazon.

Hair loss treatments like Minoxidil, finasteride, and RU58841, focusing on their effectiveness and side effects. It also highlights the disparity in medical research funding between hair loss and conditions like endometriosis.

The user is currently using finasteride and minoxidil and is considering adding microneedling and either RU58841 or Pyrilutamide for potential hair regrowth. They previously used microneedling, RU58841, and oral minoxidil before their hair transplant.

The user experienced hair loss after chikungunya and started PRF (platelet-rich fibrin) injections with injectable Dutasteride, noticing new hair growth. They are hopeful for continued improvement.

The conversation is about finding a legitimate and affordable Chinese source for RU58841 powder for hair loss treatment. It suggests choosing a vendor with good reviews and testing the product for authenticity.

Pyrilutamide is being discussed for hair loss treatment, with one user reporting no success after six months and another using it alongside finasteride for two months. The conversation seeks recommendations and experiences with pyrilutamide.

Pelage is moving to Phase III clinical trials for PP405, a hair loss treatment, with results to be presented at a medical meeting. Users express skepticism and hope, comparing it to existing treatments like Minoxidil and finasteride, while discussing the potential for new hair growth in previously bald areas.

The conversation is about the anticipation of results for a hair loss treatment study, specifically for GT20029, with expectations for the results to be released in the first quarter of 2024. No specific treatments were discussed.